Atomoxetine is a norepinephrine reuptake inhibitor approved for the treatment of attention deficit hyperactivity disorder (ADHD). The brand name is Strattera. The initial therapeutic effects of atomoxetine usually take 2–4 weeks to become apparent. There has been some suggestion that atomoxetine might be a helpful adjunct in people with major depression, especially in cases where ADHD occurs comorbidly to major depression.
Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively).
5-HT Receptor Inhibitors Related Products:
Iloperidone; Olanzapine; Clozapine; Agomelatine; Duloxetine hydrochloride; Duloxetine; Alosetron hydrochloride; Palonosetron hydrochloride; Lurasidone; Lurasidone hydrochloride; Ramosetron Hydrochloride